Skip to main content

Table 1 Patient and tumor characteristics

From: SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

  Primary tumor (n = 50) Recurrent tumor (n = 17)
Sex
 Male 34 12
 Female 16 5
Median age in years (range) 61 (19–76) 50 (19–66)
Site of primary disease
 Extremity 30 10
 Trunk 19 7
 Head & Neck 1 0
Site of recurrent disease NA  
 Local 8
 Distant 9
Histology
 Undifferentiated pleomorphic sarcoma (UPS) 32 6
 Leiomyosarcoma (LMS) 6 1
 Liposarcoma (LPS) 6 1
 Synovial sarcoma (SS) 3 4
 Malignant peripheral nerve sheath tumor (MPNST) 2 3
 Fibrosarcoma (FS) 1 2
Prior treatment
 Gemcitabine/docetaxel 27 2
 Doxorubicin/ifosfamide 17 1
 Doxorubicin/dacarbazine 0 1
 None 7 13
 Radiation 2 0